Dr Bill Shingleton
Driving Translation of Cell-Based Therapies: An International Consortia to Develop Tools for Safety Assessment.
Cell-based therapies show great therapeutic promise, but to realize their full clinical potential there is a need for greater understanding of their mode of action, how they migrate after administration to deliver their therapeutic benefits, and whether their localization or distribution may cause safety issues. Currently, there are few recognized and established tools or approaches to monitor these cell-derived therapies to achieve such understanding. The Health and Environmental Sciences Institute (HESI) has formed an international, multi-disciplinary team of experts to address this issue.
Since its inception in December 2015, the Cell Therapy – Tracking, Circulation and Safety (CT-TRACS) committee has gathered about 50 members from 29 organizations across the United States, Europe and Japan. The focus of the group has been narrowed down to Cell Fate, i.e., distribution, survival/engraftment and phenotype, post-administration, in vivo, as well as evaluating the tumorigenic potential of cell-based therapies. The Committee’s focus will be to: 1) evaluate current tools and methods employed to assess the safety of cell-based therapies; 2) develop recommended best practices for application of available tools for safety assessment of cell therapies and identify gaps in information required to assess safety; 3) promote our activities through workshops and publications. The CT-TRACS project is open to all current HESI members as well as new participants with relevant technical expertise. The program also seeks creative funding partners and encourages inquiries by those with interest in providing financial support for these innovative efforts.
Technical Lead with GE Healthcare Life Sciences’ Core Imaging R&D, based in Amersham, UK. Core Imaging manufactures contrast media and radioactive agents for use in diagnostic imaging. I am focused on cell therapy and digital applications. Prior to joining GE, I spent 10 years in fast moving consumer goods R&D with Unilever, developing technology for skin care. Before embarking on industrial research held academic posts at University of Newcastle-Upon-Tyne investigating the mechanisms of cartilage destruction in Rheumatoid Arthritis. My PhD was obtained from the University of Cambridge, School of Veterinary Medicine studying Equine developmental joint disease and I hold a Bachelor’s degree in Biological Sciences from Bristol Polytechnic.